Method of modulating memory effector T-cells using CD2-binding agent, and compositions

Method of modulating memory effector T-cells using CD2-binding agent, and compositions

  • CN 100,473,417 C
  • Filed: 08/31/1999
  • Issued: 04/01/2009
  • Est. Priority Date: 08/31/1998
  • Status: Active Grant
First Claim
Patent Images

1. dosage is enough to the purposes of CD2 bonding agent LFA-3 polypeptide in the pharmaceutical composition of the described disease of preparation treatment that selectivity reduces the lymphocytic effective dose of the positive memory effect T of CD45 RO of the patient with medical conditions, and wherein this disease is selected from arthritic psoriasis, multiple sclerosis, atopic dermatitis, uveitis, inflammatory bowel, segmental enteritis, ulcerative colitis and cutaneous T cell lymphoma.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×